IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE

IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE

The article is dedicated to one of the most important issues of modern neonatology – prevention of respiratory-syncytial virus infection, which is a frequent cause of bronchiolites and pneumoniae in infants and neonates, especially premature infants. The latter belong to the high-risk group for the...

Full description

Bibliographic Details
Main Author:	E. S. Keshishyan
Format:	Article
Language:	English
Published:	Paediatrician Publishers, LLC 2013-07-01
Series:	Pediatričeskaâ Farmakologiâ
Subjects:	respiratory-syncytial virus infection epidemiology morbidity consequences risk groups prevention palivizumab efficacy safety children neonates premature infants
Online Access:	https://www.pedpharma.ru/jour/article/view/191

Similar Items

Immunoprophylaxis of Respiratory Syncytial Virus Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

Patient equity and respiratory syncytial virus Immunoprophylaxis
by: H. Cody Meissner
Published: (2019-01-01)

Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use
by: Silva Camila de A, et al.
Published: (2012-05-01)

Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
by: Bernhard Resch, et al.
Published: (2017-04-01)

Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link
by: Piedimonte Giovanni
Published: (2002-06-01)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
by: Alessandro Rocca, et al.
Published: (2021-04-01)

Cost effectiveness of a protocol using palivizumab in preterm infants
by: Yolanda Hernández-Gago, et al.
Published: (2017-03-01)

Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations
by: André Ricardo Ribas Freitas, et al.
Published: (2016-01-01)

IMMUNOPROPHYLAXIS OF SEVERE RESPIRATORY-SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA: RESULTS OF 4 EPIDEMIC SEASONS
by: A. A. Baranov, et al.
Published: (2012-12-01)

RESPIRATORY SYNCYTIAL VIRUS INFECTION IN INFANTS
by: K. V. YEVDOKIMOV, et al.
Published: (2017-05-01)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
by: Roseane Porfírio de Souza, et al.
Published: (2019-08-01)

IMMUNOPTOPHYLAXIS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN UNDER RISK OF HEAVY COURSE OF THE DISEASE: PRELIMINARY RESULTS OF IMPLEMENTING THE MOSCOW PROGRAM
by: A. A. Korsunskiy, et al.
Published: (2012-06-01)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
by: Rodica Gilca, et al.
Published: (2020-12-01)

Perinatal respiratory infections and long term consequences
by: Luciana Indinnimeo, et al.
Published: (2015-10-01)

Survival of recombinant monoclonal and naturally-occurring human milk immunoglobulins A and G specific to respiratory syncytial virus F protein across simulated human infant gastrointestinal digestion
by: Jiraporn Lueangsakulthai, et al.
Published: (2020-10-01)

Immunoprophylaxis of respiratory syncytial virus: global experience
by: Simoes Eric AF
Published: (2002-06-01)

Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing
by: Kimpen Jan LL
Published: (2002-06-01)

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study
by: Ruomei Xu, et al.
Published: (2020-10-01)

A CLINICAL AND ECONOMICAL ANALYSIS OF THE RESULTS PRODUCED BY THE PROGRAM OF RSV-INFECTION PROPHYLAXIS DURING THE EPIDEMIOLOGICAL SEASON OF 2012/2013 IN MOSCOW
by: V. I. Ignat'eva, et al.
Published: (2013-11-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan
by: Hidetomi Yamagami, et al.
Published: (2019-03-01)

Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model
by: Jiraporn Lueangsakulthai, et al.
Published: (2020-02-01)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
by: Jesse Papenburg, et al.
Published: (2012-01-01)

Respiratory syncytial virus infection in children with congenital heart defects: Problem relevance and prevention guidelines
by: E. L. Bockeria, et al.
Published: (2016-03-01)

Modern Approaches in management of Children with Acute Bronchiolitis
by: Alexander A. Baranov, et al.
Published: (2020-02-01)

Bronchiolitis - diagnostic and therapeutic difficulties in pediatric patients
by: Iwona Kowalska, et al.
Published: (2020-03-01)

Palivizumab e virus respiratorio sinciziale: una panoramica
by: Paolo Manzoni
Published: (2011-07-01)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
by: Antonino Capizzi, et al.
Published: (2017-08-01)

Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain
by: Ralph Schmidt, et al.
Published: (2017-12-01)

Experience of passive immunoprophylaxis against respiratory syncytial viral infection in children born with very low and extremely low body weight
by: A. K. Mironova, et al.
Published: (2020-09-01)

Respiratory syncytial viral infection in children. Role in the structure of respiratory pathology and clinical and immunological features
by: V. V. Sokolovskaya, et al.
Published: (2020-03-01)

Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation
by: Baidya Nath P. Sah, et al.
Published: (2020-08-01)

Factors Affecting the Immunity to Respiratory Syncytial Virus: From Epigenetics to Microbiome
by: Wendy Fonseca, et al.
Published: (2018-02-01)

Epidemiology and Seasonality of Childhood Respiratory Syncytial Virus Infections in the Tropics
by: Manika Suryadevara, et al.
Published: (2021-04-01)

Respiratory syncytial virus, infants and intensive therapy
by: Ieda Aparecida Correa Bueno, et al.

Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV
by: Rika Gomi, et al.
Published: (2018-12-01)

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports
by: Renato Cutrera, et al.
Published: (2019-11-01)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
by: Saleh al-Alaiyan, et al.
Published: (2015-02-01)

Purification of Antibodies From Human Milk and Infant Digestates for Viral Inhibition Assays
by: Baidya Nath P. Sah, et al.
Published: (2020-08-01)

Seroepidemiology of respiratory syncytial virus infection in rural and semi-rural areas of the Littoral region of Cameroon
by: Henshaw Mandi, et al.
Published: (2021-02-01)